Pfizer R&D Emphasizes M&A; Deal Structure, Integration To Be More Flexible
Executive Summary
Pfizer anticipates that one-third of the six new products the company expects to launch annually beginning in 2011 will derive from enhanced external sourcing efforts
You may also be interested in...
Pfizer Promotes Global R&D VP Mackay To Head Unit, Opens Biotech Center
Pfizer, as part of its ongoing efforts to reinvent its R&D model, is aiming to accelerate product development under a new leadership team and establish a significant presence in biotechnology with a new facility devoted to "bioinnovation.
Pfizer Promotes Global R&D VP Mackay To Head Unit, Opens Biotech Center
Pfizer, as part of its ongoing efforts to reinvent its R&D model, is aiming to accelerate product development under a new leadership team and establish a significant presence in biotechnology with a new facility devoted to "bioinnovation.
Pfizer’s Manufacturing Cost-Cutting May Leave Little Capacity For Growth
Following its restructuring, Pfizer's in-house manufacturing capacity will support approximately $48 billion in sales